Entrada Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
TRDA$5.25+11.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss
(In thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Collaboration revenue | $20,558 | $59,120 |
| Operating expenses: | ||
| Research and development | 32,074 | 28,608 |
| General and administrative | 10,274 | 9,399 |
| Total operating expenses | 42,348 | 38,007 |
| (Loss) income from operations | (21,790) | 21,113 |
| Other income: | ||
| Interest and other income | 4,441 | 4,214 |
| Total other income | 4,441 | 4,214 |
| (Loss) income before provision for income taxes | (17,349) | 25,327 |
| Provision for income taxes | — | 1,831 |
| Net (loss) income | $(17,349) | $23,496 |
| Net (loss) income per share, basic | $(0.42) | $0.70 |
| Net (loss) income per share, diluted | $(0.42) | $0.68 |
| Weighted‑average common shares outstanding, basic | 41,073,732 | 33,497,072 |
| Weighted‑average common shares outstanding, diluted | 41,073,732 | 34,790,925 |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on marketable securities | 480 | (441) |
| Total other comprehensive income (loss) | 480 | (441) |
| Total comprehensive (loss) income | $(16,869) | $23,055 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.